Autologous RAK cell therapy (Cancer Hospital Chinese Academy of Medical Sciences/Takara BioTakara Biomedical Technology)
自体RAK细胞（中国医学科学院肿瘤医院/宝日医生物技术）
Report date: 2023/06/28 20:00:26
Base Information
Drug NameAutologous RAK cell therapy (Cancer Hospital Chinese Academy of Medical Sciences/Takara BioTakara Biomedical Technology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[7]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChinese Academy Of Medical SciencesTakara Biomedical Technology (Beijing) Co LtdPuhua Saier Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesTakara Biomedical Technology (Beijing) Co LtdPuhua Saier Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active Indications +[7]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A